MicroRNAs in veterinary viral diseases: A comprehensive review from molecular mechanisms to clinical translation
- 1Department of Clinical Sciences, Faculty of Veterinary Medicine, Kaz. C. Islamic Azad University, Kazerun, Iran
- 2University of Applied Science and Technology, Fars, Iran
- 3Department of Agricultural Biotechnology, College of Agriculture, Jahrom University, Jahrom, P.O. Box 74135-111, Iran; Corresponding author.
Abstract
MicroRNAs (miRNAs) are small non-coding RNA molecules, approximately 22 nucleotides in length, that regulate post-transcriptional gene expression and have emerged as pivotal modulators of host–virus interactions. Veterinary viral diseases continue to pose substantial challenges to animal health, livestock productivity, food security, and public health, particularly due to their zoonotic potential. While miRNA research has advanced considerably, a comprehensive and critically integrated understanding of their biological functions and clinical applications across veterinary viral diseases remains incomplete. This comprehensive critical narrative synthesis addresses four overarching research questions: (1) What conserved and species-specific miRNA-mediated mechanisms govern major veterinary viral diseases? (2) What contextual factors determine antiviral vs. proviral duality? (3) To what extent do circulating miRNA signatures offer diagnostic and prognostic utility? (4) What translational barriers currently prevent clinical implementation, and how can the One Health framework help overcome them? Integrating three interconnected dimensions—molecular mechanisms, pathogen-specific responses, and translational applications—the review synthesizes evidence across PRRSV, avian oncogenic viruses (MDV, ALV), the immunosuppressive IBDV, FMD, BVDV, Ebola, Hendra, Rabies, and aquatic viral diseases. A key contribution of this review is the proposal of a four-axis contextual framework that explains the antiviral/proviral duality of miRNAs, and a 'One miRNA, One Health' convergence model with a concrete implementation roadmap. Key findings include: (a) a four-axis contextual framework (cell type, infection stage, viral strain, host–viral miRNA competition) that explains the antiviral/proviral duality; (b) virus-encoded miRNAs (v-miRNAs) as lower-risk therapeutic targets due to their absence from uninfected host genomes; (c) circulating miRNA biomarkers validated only at proof-of-concept stage (TRL 1–3), with no veterinary product yet at TRL ≥4; and (d) zoonotic conservation of miR-155, miR-146a, miR-21, and miR-122 across human and veterinary pathogens, supporting a ‘One miRNA, One Health’ convergence strategy. Critical short-term priorities are standardized pre-analytical protocols, open-access veterinary miRNA databases, and multicenter validation in natural infection cohorts.
Related
- Novel strategies against drug-resistant tuberculosis: a comprehensive review from molecular mechanisms to clinical translation
- Multi‐omics integration driving precision medicine in non‐small cell lung cancer: From molecular mechanisms to clinical translation
- Ketogenic Dietary Therapies and β-Hydroxybutyrate as Modulators of Mitochondrial Function: From Molecular Mechanisms to Clinical Translation
- Ferroptosis in cancer: molecular mechanisms, tumour microenvironment, therapeutic resistance, and clinical translation.
- Targeting oral cancer with curcumin and its structural analogs: molecular mechanisms, pharmacokinetic optimization, and clinical translation.
BibTeX
@article{choobineh2026micrornas,
title = {{MicroRNAs in veterinary viral diseases: A comprehensive review from molecular mechanisms to clinical translation}},
author = {Mohamad Reza Choobineh and Daryoosh Choobineh and Behzad Hajieghrari},
journal = {Virus Research},
year = {2026},
month = nov,
doi = {10.1016/j.virusres.2026.199800},
url = {https://doi.org/10.1016/j.virusres.2026.199800},
note = {CC BY},
}
RIS
TY - JOUR
TI - MicroRNAs in veterinary viral diseases: A comprehensive review from molecular mechanisms to clinical translation
AU - Mohamad Reza Choobineh
AU - Daryoosh Choobineh
AU - Behzad Hajieghrari
PY - 2026
DA - 2026/11/16
JO - Virus Research
DO - 10.1016/j.virusres.2026.199800
UR - https://doi.org/10.1016/j.virusres.2026.199800
AB - MicroRNAs (miRNAs) are small non-coding RNA molecules, approximately 22 nucleotides in length, that regulate post-transcriptional gene expression and have emerged as pivotal modulators of host–virus interactions. Veterinary viral diseases continue to pose substantial challenges to animal health, livestock productivity, food security, and public health, particularly due to their zoonotic potential. While miRNA research has advanced considerably, a comprehensive and critically integrated understanding of their biological functions and clinical applications across veterinary viral diseases remains incomplete. This comprehensive critical narrative synthesis addresses four overarching research questions: (1) What conserved and species-specific miRNA-mediated mechanisms govern major veterinary viral diseases? (2) What contextual factors determine antiviral vs. proviral duality? (3) To what extent do circulating miRNA signatures offer diagnostic and prognostic utility? (4) What translational barriers currently prevent clinical implementation, and how can the One Health framework help overcome them? Integrating three interconnected dimensions—molecular mechanisms, pathogen-specific responses, and translational applications—the review synthesizes evidence across PRRSV, avian oncogenic viruses (MDV, ALV), the immunosuppressive IBDV, FMD, BVDV, Ebola, Hendra, Rabies, and aquatic viral diseases. A key contribution of this review is the proposal of a four-axis contextual framework that explains the antiviral/proviral duality of miRNAs, and a 'One miRNA, One Health' convergence model with a concrete implementation roadmap. Key findings include: (a) a four-axis contextual framework (cell type, infection stage, viral strain, host–viral miRNA competition) that explains the antiviral/proviral duality; (b) virus-encoded miRNAs (v-miRNAs) as lower-risk therapeutic targets due to their absence from uninfected host genomes; (c) circulating miRNA biomarkers validated only at proof-of-concept stage (TRL 1–3), with no veterinary product yet at TRL ≥4; and (d) zoonotic conservation of miR-155, miR-146a, miR-21, and miR-122 across human and veterinary pathogens, supporting a ‘One miRNA, One Health’ convergence strategy. Critical short-term priorities are standardized pre-analytical protocols, open-access veterinary miRNA databases, and multicenter validation in natural infection cohorts.
SN - 1872-7492
ER -